TY  - JOUR 
AU  - Rivera, F.
AU  - Romero, C.
AU  - Jimenez-Fonseca, P.
AU  - Izquierdo-Manuel, M.
AU  - Salud, A.
AU  - Martinez, E.
AU  - Jorge Fernández, Monica
AU  - Arrazubi, V.
AU  - Mendez, J. C.
AU  - Garcia-Alfonso, P.
AU  - Reboredo Lopez, Margarita
AU  - Barriuso, J.
AU  - Munoz-Unceta, N.
AU  - Jimeno, R.
AU  - Lopez, C.
PY  - 2019
SN  - 0344-5704
UR  - http://hdl.handle.net/20.500.11940/16011
AB  - PURPOSE: The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve...
LA  - eng
KW  - Stomach Neoplasms
KW  - Adult
KW  - Middle Aged
KW  - Fluorouracil
KW  - Follow-Up Studies
KW  - Survival Rate
KW  - Oxaloacetates
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Esophagogastric Junction
KW  - Humans
KW  - Treatment Outcome
KW  - Deoxycytidine
KW  - Prospective Studies
KW  - Aged
TI  - Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
DO  - 10.1007/s00280-019-03820-7
T2  - CANCER CHEMOTHERAPY AND PHARMACOLOGY
M2  - 1175
KW  - CHUAC
KW  - CHUVI
VL  - 83
ER  -